Ajan Reginald is a Biotech entrepreneur and the co-founder and Chief Executive of Celixir plc. Celixir plc is a British cellular medicines company with drugs in late-stage clinical trials for heart failure and tendon repair and an extensive in-house product pipeline.
Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment.
Association Of The British Pharmaceutical Industry
Paula Maria M. Alves
Paula M Alves graduated in Biochemistry at the Faculdade de Ciências da Universidade de Lisboa, and holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.
Magdalena Tary-Lehmann is a Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL) and Adjunct Associate Professor of Case Western Reserve University (CASE) Department of Pathology.
Senior Consultant - Regulatory Affairs - Gene and Cell Therapies
Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies including virally vectored gene therapy
Jean-Pierre joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management, clinical operations and regulatory affairs
Dr. McAllister is the Executive Director at the Amnion Foundation, a public stem cell bank that is developing technology pioneered by Dr. Anthony Atala at Mass General Hospital in Boston (www.amnionfoundation.org).
Sandra van Wetering is an expert in the development and manufacturing of cell-based products, and has in-depth knowledge the regulatory strategies and processes involved in development of such products,